Core Viewpoint - He Eye Hospital (301103) is primarily engaging in industry investment funds rather than direct research and production activities [1] Group 1: Company Activities - The company participates as a limited partner in the establishment of the Zhaohua (Guizhou) Health Technology Industry Development Fund, which focuses on eye health [1] - The fund primarily invests in new-generation medical health, dietary nutrition, and synthetic biology sectors [1] Group 2: Future Disclosures - The company will strictly adhere to information disclosure requirements and announce any significant developments in a timely manner [1]

蜀道装备（300540）发布公告称，公司拟与蜀道产融(四川)私募基金管理有限公司(以下简称"蜀道基金 管理公司")、蜀道(四川)股权投资基金有限公司(以下简称"蜀道基金公司")共同投资设立蜀道(四川)气体 产业股权投资基金(有限合伙)。 据了解，该基金规模为20亿元，出资方均为蜀道投资集团实际控制的实体，基金主要投向将围绕 LNG、工业气体(含特种气体、电子气体)、氢能领域设立子基金或开展直接股权投资。 特别地，上述新设基金将充分遵循"优先级保障固定收益、劣后级享有超额回报"的原则，在8年基金存 续期(4年投资期+4年退出期)内按照优先级有限合伙人(LP)、劣后级有限合伙人(LP)、普通合伙人(GP)的 顺序依次按权益份额分配收益，门槛收益率为单利年化6%。有超额收益时，90%分配给有限合伙人， 其中优先级LP和劣后级LP按照4:6分配；剩余10%分配给普通合伙人。 必须看到，做强做优以实体经济为支撑的现代化产业体系，离不开资本市场的强大支撑。 作为国内最早进入气体液化及分离产业的企业之一，蜀道装备具备完整的核心技术体系，涵盖气体分 离、提纯、液化、尾气制氢等关键环节，产品广泛应用于核反应堆、半导体制造、医疗 ...

Group 1 - The establishment of the Guangxi Liugong Zhanxing and Future Industry Investment Fund Partnership has been announced, with a total investment amount of 1 billion yuan [1] - The fund's business scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-funded by Guangxi Liugong Group Co., Ltd. and other partners [1]

Group 1: Financial Performance - The net profits attributable to shareholders for the years 2022, 2023, and 2024 were 75.57 million, 144.67 million, and 132.43 million respectively, totaling 352.67 million over three years [1][2] - Cash dividends for the years 2022, 2023, and 2024 were 84.17 million, 134.68 million, and 121.21 million respectively [2] Group 2: Regulatory Impact - The new national standard "Residential Project Specifications" issued by the Ministry of Housing and Urban-Rural Development will be implemented from May 1, 2025, mandating at least one elevator for residential buildings with four or more floors and at least two elevators for buildings with twelve or more floors [3] - The new regulations are expected to shift the elevator industry from reliance on real estate to a three-dimensional growth model encompassing new installations, retrofitting, and upgrades [3] Group 3: Corporate Governance and Strategy - Independent directors provide professional opinions and exercise voting rights independently to support the company's strategic development and protect shareholder interests [3] - The company is open to mergers and acquisitions that align with its development strategy and will disclose relevant information in accordance with regulatory requirements [6] Group 4: Market Position and Future Outlook - The company aims to maximize value for shareholders while maintaining effective communication with the capital market to align its valuation with intrinsic value [3] - Suggestions for collaboration with educational institutions to enhance talent acquisition and technology transfer were acknowledged and will be considered [4]

证券日报网讯 何氏眼科9月17日在互动平台回答投资者提问时表示，公司前期投资参与产业投资基金的 设立，主要是基于战略聚焦、专业分工，是为了围绕公司眼健康主业，在上下游产业链及相关新一代医 疗健康新兴领域寻找优质的投资标的。 （编辑 姚尧） ...

| 基本信息 5 | 法律诉讼 | 经营风险 | 经营信息 公 | | --- | --- | --- | --- | | 执行事务合伙人2 | 河南农业投资集团私募基金有限 公司 | 登记状态 2 | 存续 | | | 委派代表:刘旸(来源于中基协) | 成立日期 | 2025-09-09 | | 统一社会信用代码 7 | 91411424MAEWFGL94D | 出资额 | 50100万人民币 | | 工商注册号 | - | 纳税人识别号 2 | 91411424MAEWFGL94D | | 营业期限 | 2025-09-09 至 2032-09-09 | 纳税人资质 | - | | 北京都 | 有限合伙企业 | 行业 | 资本市场服务 | | 参保人数 | - | 英文名称 | | | 登记机关 | 柘城县市场监督管理局 | 主要经营场所 2 | 河南省商丘市柘城县邵元乡振 | | 经营范围 ♡ | | 许可项目:以私募基金从事股权投资、投资管理、资产管理等活动(须在中国证券投资基金业协会 门外滩后方可并屡经营活动。目体经营项目门相关部门联众推动共可证件并发出 | | 天眼查工商信息显示，近日，商丘市超 ...

Core Viewpoint - The company has approved the establishment of a joint investment fund aimed at the pharmaceutical industry, with a total commitment of RMB 2 billion, to enhance its competitive edge in innovative sectors [1] Investment Fund Details - The investment fund, named "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)," will be co-established with Shanghai Fuguang Private Equity Fund Management Co., Ltd., Hangzhou Industrial Investment Co., Ltd., and Hangzhou Gongshu Industrial Fund Co., Ltd. [1] - The total subscribed capital of the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] Investment Focus - The fund will primarily invest in sectors such as innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other areas related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1] - The objective of the fund is to reduce the upfront costs associated with identifying and introducing high-quality innovative projects, diversify investment risks, and consolidate resources to strengthen the company's core competencies in key areas like innovative pharmaceuticals, medical aesthetics, and industrial microbiology [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展规划，广州维力医疗器械股 份有限公司（以下简称"公司"）与橡栎医林投资（苏州）合伙企业（有限合伙）、苏州天使投资引导基 金（有限合伙）、橡栎莲芰(广州)创业投资基金合伙企业(有限合伙)于2025年6月23日签署了《维智医航 （苏州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参与设立维智医航 （苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智医航"），维智医航拟募资规模为人民币 15,000万元，公司拟认缴出资人民币3,750万元，占总认缴出资规模的25%，资金来源为自有资金。（具 体内容详见公司2025年6月24日披露于《中国证券报》、《上海证券报》、《证券时报》及上海证券交 易所网站（www.sse.com.cn）的《关于参与设立产业投资基金的公告》（2025-041））。 一、对外投资基本情况 董事会 2025年6月24日，公司参与设 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603309 证券简称：维力医疗 公告编号：2025-051 备案日期：2025年8月7日 广州维力医疗器械股份有限公司 关于参与设立产业投资基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、对外投资基本情况 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展规划，广州维力医疗器械股 份有限公司（以下简称"公司"）与橡栎医林投资（苏州）合伙企业（有限合伙）、苏州天使投资引导基 金（有限合伙）、橡栎莲芰(广州)创业投资基金合伙企业(有限合伙)于2025年6月23日签署了《维智医航 （苏州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参与设立维智医航 （苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智医航"），维智医航拟募资规模为人民币 15,000万元，公司拟认缴出资人民币3,750万元，占总认缴出资规模的25%，资金来源为自有资金。（具 体内容详见公司2025年6月24日披露于《中国证券报》、《上海证券报》、 ...

Core Viewpoint - DreamNet Technology (002123) announced its plan to invest in a private equity fund aimed at high-end equipment industry, with a target fundraising scale of 2 billion yuan [1][2]. Group 1: Investment Details - The partnership will involve DreamNet and other limited partners, with a total subscription amount of 1.54 billion yuan, and DreamNet's contribution being 50 million yuan, representing 3.2468% of the total [1][2]. - The fund's primary investment areas include industrial mother machines, laser and additive manufacturing, precision instruments, and rail transportation, with each of the first three sectors receiving at least 20% of the investment [2][3]. - The fund management will be led by Shenzhen High-tech Investment Talent Equity Investment Fund Management Co., Ltd., which was established in December 2016 [2]. Group 2: Financial Performance - For 2024, DreamNet's projected revenue is 4.404 billion yuan, a decrease of 15.87% year-on-year, while the net profit attributable to shareholders is expected to be 38.1727 million yuan, an increase of 102.09% [3]. - In the first quarter of this year, DreamNet reported a revenue of 721 million yuan, down 34.49% year-on-year, with a net profit of 3.7331 million yuan, a decline of 57.76% [3]. Group 3: M&A Activity - Recently, DreamNet is planning an acquisition, intending to purchase 100% of Hangzhou Bicheng Digital Technology Co., Ltd. for a total price of 1.28 billion yuan, while raising up to 830 million yuan in supporting funds [4].